Amedisys, Inc. (NASDAQ:AMED – Get Free Report) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 2,260,000 shares, a growth of 37.8% from the October 15th total of 1,640,000 shares. Based on an average daily volume of 387,600 shares, the days-to-cover ratio is currently 5.8 days. Approximately 7.1% of the company’s stock are short sold.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price objective for the company. in a report on Monday, July 29th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $101.00 price objective on shares of Amedisys in a report on Thursday, July 25th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $100.67.
Check Out Our Latest Research Report on AMED
Institutional Trading of Amedisys
Amedisys Price Performance
NASDAQ AMED opened at $90.05 on Friday. The stock has a market capitalization of $2.95 billion, a price-to-earnings ratio of 35.73, a PEG ratio of 1.86 and a beta of 0.78. Amedisys has a 1-year low of $89.55 and a 1-year high of $98.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The business’s fifty day moving average price is $96.04 and its 200-day moving average price is $95.80.
Amedisys (NASDAQ:AMED – Get Free Report) last announced its earnings results on Wednesday, November 6th. The health services provider reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.19). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $587.67 million during the quarter, compared to analysts’ expectations of $586.75 million. During the same period in the previous year, the business posted $0.98 earnings per share. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. On average, equities analysts predict that Amedisys will post 4.66 earnings per share for the current year.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Further Reading
- Five stocks we like better than Amedisys
- The Significance of Brokerage Rankings in Stock Selection
- Deciphering Disruption: Inside Cathie Wood’s Latest Plays
- Differences Between Momentum Investing and Long Term Investing
- MarketBeat Week in Review – 11/11 – 11/15
- Dividend Capture Strategy: What You Need to Know
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.